Literature DB >> 25428675

Catheter-associated urinary tract infections in intensive care units at a university hospital in Turkey.

Derya Keten1, Firdevs Aktas, Ozlem Guzel Tunccan, Murat Dizbay, Ayse Kalkanci, Gülsah Biter, Hamit Sirri Keten.   

Abstract

In this study, urinary catheter utilization rates, the causative agents for catheter-associated urinary tract infection (CAUTI) and their antimicrobial susceptibilities in intensive care units (ICUs) in 2009 were investigated at Gazi university hospital. We aimed to determine the causative agents and risk factors for CAUTIs, and antimicrobial susceptibilities of the pathogens; and also sensitivities of Candida spp. to antifungal agents with Microdilution and E-test. The most common etiological agents of CAUTIs were Candida spp. (34.7%). The most frequently isolated Candida spp. was C.albicans (52.4%). All C. albicans spp. were sensitive to fluconazole. Microdilution, used as a reference method to determine the sensitivity to antifungal agents, was compared with E test. E test was found to be sufficient to analyze sensitivity to amphotericin B, caspofungin, fluconazole and voriconazole, but inappropriate for itraconazole. E.coli and Klebsiella spp. were found to be causative agents for CAUTI in 20.6% and 9.9% of cases respectively. Pseudomonas spp. and Acinetobacter spp. were isolated in 14% and 8.2% of the cases, respectively. All E.coli and Klebsiella strains were found sensitive to carbapenems. Carbapenem sensitivity was found in 47.1% and 30% of the cases infected with Pseudomonas and Acinetobacter strains, respectively. According to our results, fluconazole therapy seems to be an appropriate choice for the treatment of CAUTIs caused by C.albicans. Third and fourth generation cephalosporins should not be used for empirical treatment because of the high prevalence of extended spectrum beta-lactamase production among E.coli and Klebsiella isolates.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25428675      PMCID: PMC4333973          DOI: 10.17305/bjbms.2014.4.140

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  23 in total

1.  Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Evaluation of the E test for fluconazole susceptibility testing of Candida albicans isolates from oropharyngeal candidiasis.

Authors:  E Dannaoui; S Colin; J Pichot; M A Piens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-03       Impact factor: 3.267

Review 3.  The insertion and management of indwelling urethral catheters--minimizing the risk of infection.

Authors:  F R Falkiner
Journal:  J Hosp Infect       Date:  1993-10       Impact factor: 3.926

4.  International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009.

Authors:  Victor D Rosenthal; Hu Bijie; Dennis G Maki; Yatin Mehta; Anucha Apisarnthanarak; Eduardo A Medeiros; Hakan Leblebicioglu; Dale Fisher; Carlos Álvarez-Moreno; Ilham Abu Khader; Marisela Del Rocío González Martínez; Luis E Cuellar; Josephine Anne Navoa-Ng; Rédouane Abouqal; Humberto Guanche Garcell; Zan Mitrev; María Catalina Pirez García; Asma Hamdi; Lourdes Dueñas; Elsie Cancel; Vaidotas Gurskis; Ossama Rasslan; Altaf Ahmed; Souha S Kanj; Olber Chavarría Ugalde; Trudell Mapp; Lul Raka; Cheong Yuet Meng; Le Thi Anh Thu; Sameeh Ghazal; Achilleas Gikas; Leonardo Pazmiño Narváez; Nepomuceno Mejía; Nassya Hadjieva; May Osman Gamar Elanbya; María Eugenia Guzmán Siritt; Kushlani Jayatilleke
Journal:  Am J Infect Control       Date:  2011-09-10       Impact factor: 2.918

5.  Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the E test.

Authors:  A E Simor; G Goswell; L Louie; M Lee; M Louie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-09       Impact factor: 3.267

6.  Comparison of Etest with the broth microdilution method in susceptibility testing of yeast isolates against four antifungals.

Authors:  A N Koç; S Gökahmetòğlu; M Oğuzkaya
Journal:  Mycoses       Date:  2000-09       Impact factor: 4.377

7.  Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test.

Authors:  J van Eldere; L Joosten; V Verhaeghe; I Surmont
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

8.  Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media.

Authors:  M A Pfaller; S A Messer; A Karlsson; A Bolmström
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

9.  Comparison of broth macrodilution, broth microdilution, and E test antifungal susceptibility tests for fluconazole.

Authors:  D L Sewell; M A Pfaller; A L Barry
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

10.  Intensive care unit-acquired urinary tract infections in a regional critical care system.

Authors:  Kevin B Laupland; Sean M Bagshaw; Daniel B Gregson; Andrew W Kirkpatrick; Terry Ross; Deirdre L Church
Journal:  Crit Care       Date:  2005-01-06       Impact factor: 9.097

View more
  2 in total

1.  Ceftriaxone treatment of complicated urinary tract infections as a risk factor for enterococcal re-infection and prolonged hospitalization: A 6-year retrospective study.

Authors:  Kristian Karlović; Jadranka Nikolić; Jurica Arapović
Journal:  Bosn J Basic Med Sci       Date:  2018-11-07       Impact factor: 3.363

2.  Catheter-Associated Urinary Tract Infection in Intensive Care Unit Patients at a Tertiary Care Hospital, Hail, Kingdom of Saudi Arabia.

Authors:  Mohd Saleem; Azharuddin Sajid Syed Khaja; Ashfaque Hossain; Fahaad Alenazi; Kamaleldin B Said; Soha Abdallah Moursi; Homoud Abdulmohsin Almalaq; Hamza Mohamed; Ehab Rakha; Sunit Kumar Mishra
Journal:  Diagnostics (Basel)       Date:  2022-07-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.